Study of optimization of Helicobacter pylori eradication therapy in consideration of the PK / PD in chronic hemodialysis patients

Study of optimization of Helicobacter pylori eradication therapy in consideration of the PK / PD in chronic hemodialysis patients - Eradication therapy of Helicobacter pyroli in dialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014910

Enrollment

200

Registered

2014-09-15

Start date

2014-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori-associated chronic gastritis

Interventions

standard eradication therapy PPI bid+AMPC(750) bid+CAM(200) bid for a week low-dose amoxicillin therapy PPI bid+AMPC(250) bid+CAM(200) bid for a week Individualized therapy CAM-sensitive Helic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Helicobacter pylori-associated gastritis

Exclusion criteria

Exclusion criteria: subjects with a history of H. pylori eradication therapy, a significant clinical illness (e.g. malignancy)

Design outcomes

Primary

Measure	Time frame
Success rate of eradication therapy Safety of eradication therapy	—

Countries

Japan

Contacts

Public ContactShu Sahara

Hamamatsu University School of Medicine First Department of Medicine

ss812765@hama-med.ac.jp053-435-2261

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026